Michael Dorato has over 40 years of experience as a researcher and global leader of safety and efficacy in the pharmaceutical and CRO industries. Prior to joining Inotiv in May 2019 as part of the Smithers Avanza toxicology services acquisition, he was executive vice president of toxicology services at Smithers Avanza, and vice president and CSO of global discovery services at Covance. He also served as executive director of toxicology and Greenfield Laboratories site head at Eli Lilly and Co. for 30 years. In these positions, he led global organizations in safety and efficacy lead optimization, investigative and regulatory toxicology, discovery and late phase pathology, animal welfare, molecular and anatomical imaging, in vivo pharmacology, developmental and reproductive toxicology, veterinary medicine, and model development.
Dorato is a member of the Society of Toxicology and the American College of Toxicology and is active as a mentor for new professionals. He has held adjunct professorships at St. John’s University and Butler University and is a visiting scholar at St. John’s University, where he received his PhD in pharmacology.